![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 75.00 | 73.00 | 77.00 | 75.00 | 75.00 | 75.00 | 22,023 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -6.93 | 49.49M |
RNS Number:1935L Celsis International PLC 25 May 2000 Board Change On 28th January 2000 Celsis International plc announced the appointment of Tony Rouse to the Board as Finance Director. However due to family circumstances he has been unable to pursue this role. An interim finance consultant is in place and the board of Celsis is seeking a successor. Enquiries: Celsis International plc Jack Rowell, Chief Executive +44 (0) 1223 426008 Jenny Parsons, Investor Relations +44 (0) 1223 426008 Brunswick Communications James Garthwaite +44 (0) 207 4045959 END BOAKKPKNCBKKBPB
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions